Best Infectious Diseases Companies in Netherlands
The 53 best Infectious Diseases companies in Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Crucell.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Netherlands
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AIMM Therapeutics Develops therapeutic human monoclonal antibodies for infectious diseases and cancer | — | — | Funding Raised | 9 | Jan de Vries CEO | — | 196 patents Ex vivo generation of stable antibody‑producing B‑cell lines for therapeutic antibodies | — |
| 2 | Amplino Remote diagnostics using real time PCR for the detection of pathogens | — | — | Unfunded | — | Wouter Bruins Founder | — | — | — |
| 3 | AMT Biopharma Developer of human gene based therapies | — | — | Acqui-Hired | — | Jorn Aldag CEO | — | — | — |
| 4 | Biosenz Lab-on-chip device for infectious diseases | — | — | Deadpooled | — | Johan Oosterheert Founder | — | — | — |
| 5 | Check-Points Developer of diagnostic tests for the detection of diseases caused by bacteria | — | — | Unfunded | 27 | — | — | 15 patents Rapid detection and identification of microorganisms, focusing on drug‑resistance profiling. | — |
| 6 | Cyto-Barr Provider of diagnostics and therapeutics for viral infections | — | — | Unfunded | — | Jaap Middeldorp Founder & CEO | — | 4 patents Identification of EBV latent membrane protein extracellular domains for antibody therapeutics | — |
| 7 | DDL Diagnostic Laboratory Molecular diagnostics testing and assay development services | — | — | Acquired | 350 | — | — | — | — |
| 8 | Detect Diagnostic Bacterial detection system | — | — | Funding Raised | 10 | — | — | — | — |
Top 12 Infectious Diseases companies in Netherlands
#1
Series B · Amsterdam, North Holland · founded 2020 · 80 employees$200Mraised▾
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa. It develops nasal sprays that stop initial infection, prevent onward transmission, protect broadly against existing and new viruses, and provide universal protection, regardless of an individual’s immune history or comorbidities. The company focuses on harnessing mucosal immunity and broad protection by delivering antibodies directly to the nasal mucosa for immediate anti-viral protection. It develops active substances that target regions that lend themselves to lasting protection against multiple strains and entire virus families.
- Jun 2025Venture Debt$22.8M
- Jan 2025Series B$70M
- Jan 2022Series B$140M
- Mar 2021Series A$47.3M
#2
Seed · Eindhoven, North Brabant · founded 2019$17.6Mraised▾
Provider of in vitro diagnostic platforms for antibiotic testing. It offers diagnostic solutions to support doctors in making informed treatment decisions for bacterial infections. The flagship product, KAIROS, is a direct from sample device that provides rapid results, enabling healthcare professionals to administer correct antibiotics promptly. It aims to enhance patient outcomes and eliminate the spread of antibiotic resistant bacteria by streamlining the diagnostic process.
- Jan 2026Seed$17.5M
- Jan 2026Grant (prize money)—
- Sep 2023Grant (prize money)$80.9K
#3
Series D · The Hague, South Holland · founded 2005 · 120 employees$109Mraised▾
Micreos develops targeted antibacterial products to replace antibiotics. The company provides Micreos endolysin technology that can kill unwanted bacteria including antibiotic-resistant strains while leaving the beneficial bacteria intact. The company is also involved in the development of Micreos' Staphefekt SA.100 enzyme (endolysin), which can kill Staphylococcus aureus and MRSA. It is also suitable for routine maintenance therapy, for people with skin conditions with an infectious component, such as acne, eczema, psoriasis, and rosacea. The compnay products are FDA-approved.
- Oct 2022Series D$24.6M
- Dec 2021Grant (prize money)$56.6K
- Sep 2021Series D$37.3M
- Nov 2019Grant (prize money)$2.8M
#4
Acquired · Leiden, South Holland · founded 1993 · 1300 employees$443Mraised▾
Crucell focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and aluminum-free hepatitis A vaccine.
- Jan 2016Grant (prize money)$92.1K
- Sep 2009PE$443M
#5
Acquired · Bilthoven, Utrecht · founded 2012 · 371 employees$28.6Mraised▾
Bilthoven Biologicals produces large scale vaccines for infectious diseases, such as polio and tetanus. It was acquired by Poonawalla Group (Serum Institute, Indian vaccine manufacturer) in Jul.2012. The company manufacturers more than 20M vaccine units each year and sells in more than 25 countries.
- Jun 2023Grant (prize money)$28.6M
#6
Series B · Leiden, South Holland · founded 2004 · 44 employees$40.5Mraised▾
Developer of therapeutic vaccines for cancer and infectious diseases. The drug pipeline includes ISA101 which consists of13 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV 16 virus for the treatment of human papillomavirus type 16 induced diseases, including cervical cancer, most anogenital premalignant and malignant lesions, and head and neck cancer, and others.
- Jul 2021Series B$30M
- Oct 2019Conventional Debt$22.1M
- Dec 2017Grant (prize money)$2M
- Jan 2013Series A$10.6M
#7
Series A · Geleen, Limburg · founded 2014 · 9 employees$3.9Mraised▾
Developing therapies to treat life-threatening inflammation. It offer drug pipeline that targets neutralizing extracellular cytotoxic histones for the treatment of inflammationa nd sepsis.
- Jan 2024Series A$3.9M
#8
Series A · Tilburg, North Brabant · founded 2013 · 10 employees$8.3Mraised▾
Protinhi Therapeutics is an early stage company. They are developing proprietary technology and compounds, targeting diseases via protease inhibition. The company is planning to develop therapies on viral threats such as dengue, zika, and chikengunea.
- May 2023Grant (prize money)$8.3M
- Feb 2019Series A—
#9
Series B · Groningen, Groningen · founded 2006 · 16 employees$14.5Mraised▾
Mucosis is developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Its lead product candidate is SynGEM, an intranasal vaccine to prevent respiratory syncytial virus (RSV) infection. It has influenza vaccine candidate in clinical development which can be administered intranasally. Also have research programmes aimed at developing vaccines to prevent; pneumococcal related diseases and bacterial diarrhoea.
- Jan 2016Grant (prize money)$4M
- Jan 2015Series B$3.5M
- May 2014Conventional Debt$6.8M
- Apr 2014Series B$6.9M
#10
Funding Raised · Amsterdam, North Holland · founded 2020 · 28 employees$1.1Mraised▾
Provider of covid 19 testing services
- Sep 2023Grant (prize money)$1.1M
#11
Seed · Leiden, South Holland · founded 2017$416.9Kraised▾
Levels is a developer of diagnostic tools for the treatment of infectious diseases. The company has developed clinical trials to diagnose bacterial infections by identifying novel biomarkers. It enhances the use of antibiotics and the raise of antimicrobial resistance that helps in monitoring liver diseases.
- Dec 2023Seed$416.9K
- 2022Seed—
- Jan 2019Seed—
#12
Seed · Oss, North Brabant · founded 2012 · 13 employees$3.2Mraised▾
Innatoss Laboratories is focused on developing in vitro diagnostic tests for infectious diseases like Q fever and Lyme disease. The available product is a CE certified cell-mediated immunity test for Q fever known as "Q-detect". This whole blood test measures the cellular immune response to Coxiella burnetii. The test involves measurement of cytokines such as interferon-ɣ and further compared with controls. The organisation also got an EU Horizon 2020 grant for the development of a cellular Lyme diagnostic test.
- Jul 2016Grant (prize money)$2.2M
- Jul 2016Grant (prize money)$959.3K
- Jun 2015Grant (prize money)—
- Jul 2014Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in the Netherlands
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 915 Netherlands-affiliated papers.
- Amsterdam University Medical Centers112
- Radboud University Nijmegen86
- Radboud University Medical Center85
- Erasmus MC85
- Maastricht University79
- Liquid biopsy6→27
- Cancer2→11
- Computational biology1→7
- DNA methylation2→7
- Point of care5→9
- Liquid biopsy22→53
- Biomarker3→22
- Internal medicine11→25
- Biopsy3→15
- Lung cancer5→15
- Liquid biopsy7→26
- MEDLINE1→8
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1→7
- Coronavirus disease 2019 (COVID-19)1→7
- Internal medicine4→10
Where diagnostics is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.